

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
21 July 2005 (21.07.2005)

PCT

(10) International Publication Number
WO 2005/066182 A1

(51) International Patent Classification⁷: **C07D 495/04**

(74) Agents: ASAMURA, Kiyoshi et al.; Room 331, New Ohtemachi Bldg., 2-1, Ohtemachi 2-chome, Chiyoda-ku, Tokyo, 1000004 (JP).

(21) International Application Number:
PCT/JP2005/000318

(22) International Filing Date: 6 January 2005 (06.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2004-001310 6 January 2004 (06.01.2004) JP

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **TAISHO PHARMACEUTICAL CO., LTD.** [JP/JP]; 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (for US only): **NAKAZATO, Atsuro** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **OKUBO, Taketoshi** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **NOZAWA, Dai** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **TAMITA, Tomoko** [JP/JP]; c/o Taisho Pharmaceutical Co., Ltd., 24-1, Takada 3-chome, Toshima-ku, Tokyo, 1708633 (JP). **KENNIS, Ludo, E.J.** [BE/BE]; c/o Janssen Pharmaceutica N.V., Turnhoutseweg 30, Beerse, B-2340 (BE).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THIENOPYRIMIDINE AND THIENOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP



(57) Abstract: An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound,

inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.